Mizuho restated their neutral rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report released on Tuesday morning. Mizuho currently has a $16.00 target price on the stock, down from their prior target price of $30.00.

Other research analysts have also issued reports about the company. Citigroup Inc. lowered their price objective on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a buy rating for the company in a research report on Tuesday, April 25th. Vetr lowered Teva Pharmaceutical Industries Limited from a strong-buy rating to a buy rating and set a $35.15 price objective for the company. in a research report on Monday, April 24th. Credit Suisse Group reissued a buy rating and issued a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 17th. Deutsche Bank AG lowered their price objective on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a buy rating for the company in a research report on Friday, May 12th. Finally, Oppenheimer Holdings, Inc. reissued a buy rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, May 31st. Four equities research analysts have rated the stock with a sell rating, twenty have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has a consensus rating of Hold and an average price target of $35.06.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 16.21 on Tuesday. Teva Pharmaceutical Industries Limited has a 12 month low of $15.85 and a 12 month high of $52.66. The firm’s market capitalization is $16.47 billion. The firm’s 50-day moving average price is $25.37 and its 200-day moving average price is $30.35.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the prior year, the business earned $1.25 earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

WARNING: “Mizuho Reiterates Neutral Rating for Teva Pharmaceutical Industries Limited (TEVA)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/26/mizuho-reiterates-neutral-rating-for-teva-pharmaceutical-industries-limited-teva.html.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be paid a $0.085 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.10%. Teva Pharmaceutical Industries Limited’s payout ratio is presently -14.22%.

Several institutional investors have recently made changes to their positions in TEVA. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter worth $106,000. Bronfman E.L. Rothschild L.P. increased its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. Finally, Sterling Investment Advisors Ltd. increased its position in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 56.04% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.